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Abstract
FGF9 has complex and important roles in skeletal development and repair. We have previously
observed that Fgf9 expression in osteoblasts (OBs) is regulated by G protein signaling and therefore
the present study was done to determine whether OB-derived FGF9 was important in skeletal

T

homeostasis. To directly test this idea, we deleted functional expression of Fgf9 gene in OBs using

IP

a 2.3kb collagen type I promoter-driven Cre transgenic mouse line (Fgf9OB-/-). Both Fgf9 knockout

CR

(Fgf9OB-/-) and the Fgf9 floxed littermates (Fgf9fl/fl) mice were fully backcrossed and maintained in
an FBV/N background. Three month old Fgf9OB-/- mice displayed a significant decrease in

US

cancellous bone and bone formation in the distal femur and a significant decrease in cortical

AN

thickness at the TFJ. Strikingly, female Fgf9OB-/- mice did not display altered bone mass.
Continuous treatment of mouse BMSCs with exogenous FGF9 inhibited mouse BMSC

M

mineralization while acute treatment increased the proliferation of progenitors, an effect requiring

ED

the activation of Akt1. Our results suggest that mature OBs are an important source of FGF9,
positively regulating skeletal homeostasis in male mice. Osteoblast-derived FGF9 may serve a

PT

paracrine role to maintain the osteogenic progenitor cell population through activation of Akt

AC

CE

signaling.
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Introduction
The adult skeleton is a dynamic organ that supports body weight and maintains mineral
homeostasis through continuous bone remodeling at bone surfaces. This process requires
coordinated cellular activities between osteoclast and osteoblast lineage cells, in which osteoblasts

T

are responsible for regulating osteoclasts and depositing bone matrix through perceiving mechanical

IP

and biochemical cues, such as hormones and growth factors within bone marrow microenvironment

CR

(1). Parathyroid hormone (PTH) promotes osteoblast function and has emerged as a major approach
for clinical treatment of osteoporosis because of its anabolic effects. PTH activates the Gs-cyclic

US

AMP signaling pathway by acting on the PTH/PTHrP receptor 1 (PTHR1) in osteoblasts. By

AN

assessing the transcriptome of maturing osteoblasts expressing a Gs-activating engineered receptor
(Rs1) (2,3), we found that fibroblast growth factor 9 (Fgf9) was significantly down-regulated by Gs

M

signaling, suggesting a possible role for osteoblast-derived FGF9 in regulating bone homeostasis

ED

(4).

Signaling pathways initiated by the FGF ligand and FGF receptor (FGFR) system are crucial

PT

for various cellular processes, including proliferation, differentiation and survival (5). The

CE

functional link between FGF signaling and vertebral limb development has been extensively studied
(6-9). Signaling through FGFR1 and FGFR2 involve bones arise by intramembraneous ossification

AC

and mutations of FGFR1 and 2 principally induce craniosynostosis and facial abnormalities (10,11).
Signaling through FGFR3 principally affects bones that arise by endochondral ossification and
mutations in FGR3 cause several types of the human skeletal dysplasias including achondroplasia,
hypochondroplasia, thanaachondroplasia, and severe achondroplasia (11).
FGF9 expression is localized to perichondrium/periosteum, trabecular bone, and the
mesenchyme surrounding developing bones (12). FGF9 can interact with multiple FGFRs, but has
the highest affinity for FGFR3 (6,13,14). FGF9 is reported to have complex and important roles in

3
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skeletal development and repair (10,15-18). For instance, FGF9 null mice exhibit a lethal phenotype
with a limb developmental defect that is similar to achondroplasia in human (12).
Haploinsufficiency of Fgf9 represses bone fracture repair (17). Conditional over-expression of
FGF9 in cartilage caused an inhibitory phenotype of chondrocyte terminal differentiation with less

T

subchondral bone formation (6). In contrast to its diverse activities in development and physiology,

IP

the roles of the FGF9 in bone homeostasis are still unclear due to functional and structural

CR

redundancy and the similar receptor specificity across FGF ligands (5,19).

In this study, we addressed the physiological role of osteoblast-derived FGF9 by deleting its

US

expression in maturing osteoblasts using the 2.3kb collagen type I promoter driven Cre

AN

recombinase. We found that osteoblast-derived FGF9 has a sex dimorphic (male-specific) effect on
adult mouse skeleton associated with an increase in osteoblast progenitor cell proliferation and

AC

CE

PT

ED

M

suppression of osteoblast differentiation.

4
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Materials and Methods
Animals
All transgenic mouse studies were approved by and performed in accordance with the
Institutional Animal Care and Use Committees at the San Francisco Veterans Affairs Medical

T

Center and at the University of California, San Francisco.

IP

The transgenic mice with Fgf9 gene specifically depleted in osteoblasts were generated by

CR

crossing the male transgenic mice that heterogeneously harbor the Cre recombinase gene (Cre)
driven by a 2.3kb type 1 collagen promoter [STOCK Tg(Col1a1-Cre)2Bek/Mmucd, MMRRC] with

US

the female Fgf9flox/flox mice (generously provided by Dr. Fen Wang, Texas A&M Health Science

AN

Center)(20). To minimize the unnecessary genetic effects on bone metabolism, we backcrossed all
the mice to a FVB/N background. The homozygous Fgf9flox/flox mice in a FVB/N background were

M

bred by crossing the Fgf9flox/flox chimeras with the wild type FVB/N mice for 10 generations (Fig.

ED

1A). The average litter size for a FVB/N mouse breeding pair was between 8 to 10 pups in this
study. Our breeding strategy has resulted in that the offspring of each litter mice had 50% chance to

PT

be osteoblast conditional knockout mice (Co l1 (2.3)-Cre; FGF9

flox/flox

)(Fgf9

OB-/-

) and the other

CE

50% mice were likely to be FGF9flox/flox, which served as littermate controls (Fgf9 fl/fl).
All mice were group-housed at 5 mice per plastic cage, maintained in a humidity and

AC

temperature controlled facility with a 12/12 hour light/dark cycle, and fed with food and water ad
libitum. At the termination of this study, 12 week old mice were euthanized and both femurs and
tibiae were subjected to skeletal phenotype assessment as indicated below. To study bone formation
and mineralization, mice were injected with 20 mg/kg of calcein (Sigma-Aldrich, St Louis, MO,
USA) 21 and 7 days before euthanasia and with 15 mg/kg of demeclocycline (Sigma-Aldrich) 2
days before euthanasia.
Analysis of Bone Formation

5
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Mice were euthanized and femurs and tibiae were removed and dissected free from
surrounding musculature. Bones were fixed in 10% neutral-buffered formalin for 48 hours at 4C
and then stored in 70% ethanol before CT and histomorphometry. The distal femurs and tibiofibular junction (TFJ) were scanned using a Scanco VivaCT-50 µCT system (Bruttisellen,

T

Switzerland). All CT images were obtained using an X-ray energy of 55 kV with a voxel size of

IP

10.5 um and integration time of 1000 ms. The cancellous region of interest (ROI) was at a distance

CR

of 0.10 to 1.35 mm from the primary spongiosa. The cancellous ROI was assessed in distal femurs
using a global thresholding protocol with segmentation values of 0.8/1/270. Quantitative assessment

US

of diaphyseal cortex at TFJ was conducted using data from 40 slices (0.42 mm) using a global

AN

thresholding protocol with segmentation values of 0.8/1/365.
Histomorphometry

M

Following µCT analysis, the un-decalcified femurs and tibiae were embedded in methyl

ED

methacrylate and then sectioned with Jung 2065 and 2165 microtomes (Leica, 145 Bannockburn,
IL, USA). Assessment of bone formation activity at cancellous bone surfaces was performed on the

PT

unstained, 10-mm longitudinal sections from the left femur. Five-mm sections of distal femur bones

CE

were also processed for Von Kossa/Trichrome staining as previously described for static
histomorphometry (21). Assessment of cortical bone was performed on 10-mm transverse sections

AC

at TFJ. Before histomorphometry, mosaic-tiled images of distal femur and TFJ were acquired at x20
magnification with a Zeiss Axioplan Imager M1 microscope (Carl Zeiss MicroImaging,
Thornwood, NY, USA) fitted with a motorized stage. The tiled images were stitched and converted
to a single image using the Axiovision software (Carl Zeiss MicroImaGing) prior to blinded
analyses being performed using image-analysis software (Bioquant Image Analysis Corp.,
Nashville, TN, USA). Cancellous bone was assessed in the region 100 µm from the lowest point on
the growth plate, extending 1 mm down the metaphysis. To measure the number of osteoclast per
6

ACCEPTED MANUSCRIPT
bone surface in the trabecular bone, 5-μm longitudinal sections from the distal femur were stained
for tartrate resistant acid phosphatase (TRAP) (22-24). The dynamic indices of bone formation
within the same region that were measured on 10-mm sections and percent mineralizing surface
(MS/BS), mineral apposition rate (MAR), and surface-based bone-formation rate (BFR/BS) were

T

determined by Bioquant OSTEO software.

IP

RNA Extraction and RT-qPCR

CR

Both femur and tibia were isolated immediately after animals were euthanized. The
epiphyses were then removed and bone morrow was flushed with PBS. The diaphyses were kept

US

frozen in liquid nitrogen until processing. Frozen tissues were pulverized using a biopulverizer

AN

(Biospec Products, Inc., Bartlesville, OK, USA), followed by RNA extraction using RNA STAT60
(Tel-Test, Inc., Friendswood, TX, USA) and subsequent purification using Micro-to-Midi Total

M

RNA Purification Kit (Invitrogen, Carlsbad, CA, USA). cDNA was synthesized using TaqMan

ED

Reverse Transcription Reagents (Applied Biosystems, Inc., Foster City, CA, USA) and random
hexamer primers according to the recommendations of the manufacturer. Gene amplification was

PT

measured with SYBR Green using the ABI Prism ViiATM 7 real-time PCR System (Waltham, MA,

CE

USA). Analysis was carried out using the ViiATM 7 software supplied with the thermocycler. The
sequences of the primer sets have been published previously (4,23,25). The target gene expression

AC

was displayed normalized to GAPDH.
Serum Chemistry

Before euthanizing the mice, blood was collected from the abdominal inferior vein when
mice were under isoflurane inhalation anesthesia and then processed in MicroTainer serum
separator tubes (BD Biosciences, San Jose, CA, USA). Serum procollagen type I amino-terminal
propeptide (PINP) and serum pyridinoline (PYD) measurements were carried out using the
rat/mouse PINP EIA Kit AC-33F1 from Immunodiagnostic Systems (Scottsdale, AZ, USA) and the

7
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Metra Biosystems Serum PYD Kit 8019 (Metra Biosystems Inc., Santa Clara, CA, USA) according
to manufacturers’ directions.
Bone marrow stromal cell culture and mineralization in vitro
Briefly, the bone marrow plugs from 8 to 10 week old wild type FVB/N mice were flushed

T

out from both femurs and tibiae and cultured in primary culture medium, alpha modification of

IP

Eagle’s medium (-MEM; Thermo Scientific) supplemented with 10% fetal bovine serum

CR

(HyClone), 100U/ml penicillin, 100µg/ml streptomycin (Invitrogen), and 0.25µg/ml Fungizone
(26). Bone marrow stromal cells (BMSCs) were plated into 6-well plates at a density of 1.8 ~ 2.3

US

x106 cells/well. Cells were incubated in a humidified atmosphere of 5% CO2 at 37°C. On day seven,

AN

50 µg/ml ascorbic acid (Sigma-Aldrich) and 3mM ß-glycerol phosphate (Sigma-Aldrich) were
added to the primary culture media to induce osteoblastic differentiation. Media was changed every

M

2-3 days. To assess mineralization, two percent silver nitrate solution (Sigma-Aldrich) was added to

ED

cell culture dishes on day 21 for Von Kossa (VK) staining and UV-crosslinked for 10 minutes.

Cell Proliferation

PT

Stained cultures were scanned and quantified using Improvision Openlab software version 5.0.2.

CE

Effect of FGF9 on mouse BMSC proliferation was determined by measuring BrdU
incorporation using a Cell Proliferation ELISA kit (Roche Applied Science, Indianapolis, IN)(23).

AC

Briefly, mouse BMSCs were plated onto 96-well plates at a seeding density of 1x104 cells / well in
primary culture media. On day 3, 1 ~ 10 ng/ml recombinant mouse FGF9 (R&D Systems, INC,
Minneapolis, MN) was added to the media for 24 hours, and BrdU was added 4 hours prior to the
assay. The incorporated BrdU in each culture was quantified according to the manufacturer’s
instruction. The results of this assay were confirmed by repeating the experiment three times.
Protein Extraction and Immunoblotting

8
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The wild type BMSCs at confluence were treated with 5ng/ml FGF9 for 24hr. FGF9
solution was prepared in the osteogenic medium, in which the fetal bovine serum (FBS) was
omitted to eliminate the effect of serum components on the phosphorylation of Akt and Akt1.
Whole cells protein lysates were prepared using RIPA buffer (50 mM sodium chloride, 1.0% NP-

T

40, 0.5% sodium deoxycholate, 0.1% SDS (sodium dodecyl sulfate), 50 mM Tris, pH 8.0) plus

IP

protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific) and measured the

CR

concentrations using BCA assay (Thermo Fisher Scientific). Protein samples (10-15ug/lane) were
resolved by SDS-PAGE (10% separating gel), transferred to PVDF membranes, and subjected to

US

immunoblot analysis with specific antibodies against Akt; Akt1, phosphorylated Akt; and

AN

phosphorylated Akt1 (Cell Signaling) at the dilution of 1:1000. Detection was made by enhanced
chemiluminescence (ECL) using SuperSignal West Dura Extended Duration Substrate (Thermo

M

Fisher Scientific). Data was captured using Fujifilm LAS 4000 (Fuji Medical Systems, USA).

ED

Statistical Analysis

Statistical significance was ascertained by a two-tailed Student's t test or, where indicated,

AC

CE

PT

by two-way ANOVA. α ≤ 0.05 was considered significant.

9
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Results:
Loss of Fgf9 in Osteoblasts Has no Effect on Bone Growth
FGF9 participates in multiple steps of endochondral ossification to regulate skeletal
development in the proximal limb (6). The FGF9 null mice have rhizomelic limb shortening,

T

initiated at the earliest stages of skeletal growth. However, specific knockout Fgf9 gene in

IP

osteoblasts (OBs) did not replicate the skeletal phenotypes in Fgf9 null mice (12). We did not
fl/fl

vs. Fgf9

OB-/-

: male,

CR

observe a significant change of body weights up to 3 months of age (Fgf9
24.13 ± 0.59 vs. 23.3 ± 0.62 g; female, 18.42 ± 0.27 vs. 17.8 ± 0.97 g).

US

Loss of Fgf9 in Osteoblasts Decreases Cancellous Bone Formation in Adult Male Bones

AN

To test the specificity of Cre gene expression, we bred the Co l1 (2.3)-Cre mice with a line
of Rosa tomato red mice (generously provided by Dr. Ann Zovein, University of California San

M

Francisco, CA) (Fig 1B). The Cre recombinase is demonstrated to be expressed in OBs and

ED

osteocytes (OCTs) in adult Coll (2.3)-Cre; td/Tomato Red mice (Fig 1B). To test the efficiency of
Fgf9 deletion in Fgf9OB-/- mice, we also performed reverse transcription end point PCR on RNA

PT

extracted from long bones and demonstrated that FGF9 gene was successfully excised by Cre

CE

recombinase (Fig. 1C)(20) and as expected, the conditional Cre-loxp recombination dramatically
decreased Fgf9 mRNA level in both male and female Fgf9OB-/- mice (Fig. 1D).

AC

MicroCT assessment demonstrated that Fgf9 deletion led to a dramatic decrease in
cancellous bone fractional volume (BV/TV) at distal femur in male, but not female, Fgf9 OB-/- mice
(Fig. 2A and Table 1).

The decrease was mainly associated with a significant decrease in

trabecular thickness (Tb.Th) (p<0.001) and an increase in trabecular separation (Tb.Sp) (Table. 1).
In contrast, Fgf9 deficiency did not change trabecular number (Tb.N) (Table. 1). The effects of
Fgf9 gene deletion on adult mouse bones were also evaluated by histomorphometry. The 3 month
old male Fgf9

OB-/-

mice showed a significant decrease in cancellous BV/TV and Tb.N, and a

10
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significant increase in Tb.Sp, compared to the age and sex-matched Fgf9

fl/fl

mice (Fig. 2B).

However, the female transgenic mice displayed no change in BV/TV, Tb.Th, Tb.N, and Tb.Sp at
the distal femur (Fig. 2B). The osteoblasts sitting at the trabecular surface (N.Ob/BS) was also
counted. It was found that N.Ob/BS was significantly lower in the male but not in the female Fgf9
mice, compared to the age-matched controls (Supplemental Fig. 1A).

T

fl/fl

IP

To reveal the mechanism by which the loss of Fgf9 in osteoblasts led to decreased

CR

cancellous factional bone volume, we performed dynamic histomorphometry on the same bones
(Fig. 2C). A sexual dimorphic response of bone formation to the Fgf9 deletion in osteoblasts was

OB-/-

mice displayed decreased MS/BS and BFR. However, trabecular MAR was not

altered in male Fgf9

OB-/-

AN

Male Fgf9

US

also observed at the distal femur by measuring fluorescence labeled trabecular surfaces (Fig. 2C).

mice. In contrast, there were no differences seen in the parameters of

M

dynamic histomorphometry between female Fgf9 OB-/- mice and sex matched littermate control mice

ED

(Fig. 2C).

Loss of Fgf9 in Osteoblasts Decreases Cortical Bone Formation in Adult Male Bones

PT

The cortical bone shell is a key determinant of bone strength and fracture risk and thins

CE

rapidly with age (27,28). Effects of the conditional knockout of FGF9 on cortical bone volume,
cortical bone thickness, and bone marrow area were assessed at the TFJ by µCT (Fig. 3A and

AC

Table 1.). In male mice, there was no difference in tissue volume between the knockout and the
littermate control mice. However, the FGF9 deletion resulted in a slight and statistically significant
decrease in bone volume and cortical bone thickness (Ct. Th). There were no significant differences
observed between female control and transgenic mice (Table 1.). The changes in cortical bone were
further confirmed by histological analysis of the TFJ in Fgf9OB-/- (Fig. 3B). In males, loss of Fgf9 in
osteoblasts did not affect the cortical periosteal perimeter. The endosteal perimeter and bone
marrow area were significantly greater while cortical thickness was significantly smaller at the TFJ

11
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in male Fgf9OB-/- mice (Fig. 3B). This result demonstrates that the loss of bone that occurred at the
TFJ was mainly at the endosteal surface. The decreased bone formation at both periosteal and
endosteal surfaces of the TFJ was mainly due to the decreased mineralizing surface in male Fgf9 OB/-

. There were no significant changes in any of the cortical parameters in female mice (Fig. 3C). In

T

addition, it has been found that the Ps.BFR is decreased in Fgf9 OB-/- male mice without any

IP

significant changes in periosteal perimeter (Ps.Pm) (Fig. 3B and 3C). The mice used in this study

CR

were at age of 3 months and by then the peak bone mass has already been established (29). Our
result suggests that the source of FGF9 from mature osteoblasts possibly does not impact the

US

cortical bone accrual during growth but may affect the cortical bone expansion during aging.

AN

Endogenous Fgf9 Restrains the Function of Mature Osteoblasts
We examined the effects of FGF9 deletion on the expression of genes in the femoral

M

diaphysis. We observed no change in the expression of the early osteogenic marker genes, such as

ED

Osx and Runx2. Surprisingly, Alp, Col1, Ocn, and Dmp1 mRNA expression was significantly higher
in male Fgf9OB-/-, compared to age-matched Fgf9

fl/fl

mice. There were no significant differences

PT

observed between female transgenic and control mice, in regards to gene expression (Fig. 4). It has

CE

been reported that Fgf9 is important for promoting skeletal vascularization and global Fgf9 null
mice displayed delayed osteogenesis due to defects in angiogenesis (12). However, we did not

AC

detect a significant change pecam1 mRNA level in the Fgf9OB-/- mice (data not shown).
Bone Resorption in Adult Fgf9 OB-/- Mouse Bone Was not Altered
In a previous study, Fgf9 null mice were found to display a reduction in osteoclast numbers
in the perchondrondrium and primary spongiosa of the developing long bones (12). To examine if
Fgf9 deficiency in osteoblasts affects osteoclastogenesis in adult skeleton, we performed TRAP
staining and found that the specific deletion of Fgf9 in osteoblasts did not alter the number of
osteoclasts (N.Oc/BS) within the distal femur (Fig. 5). Consistent with this finding, serum PYD was

12
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not changed, either (Fig. 5). Although the levels of Opg and Rankl mRNA were increased in males
(data not shown), the ratio of OPG/RANKL was not significantly altered by deleting Fgf9 (Fig. 5).
Exogenous FGF9 Stimulates Proliferation of BMSCs
We demonstrated that Fgf9 OB-/- mice displayed an osteoblastic phenotype, in which deletion

T

of Fgf9 in osteoblasts led to a low bone mass due to a decreased bone formation rate in male

IP

skeleton. We have carried out additional studies to determine whether there is a cell autonomous

derived from male Fgf9

OB-/-

CR

autocrine role for FGF9 in promoting osteogenesis. We found that bone marrow stromal cells
mice displayed osteogenic differentiation that was comparable to that

US

seen in cultures from WT mice (Supplemental Figure 1B). These findings suggest that osteoblast

AN

derived FGF9 promotes osteogenesis through paracrine effects on osteoprogenitors. To test this
hypothesis, we cultured BMSCs from wild type mice and the effect of exogenous FGF9 on BMSC

M

proliferation was examined using a BrdU incorporation assay. It was found that treatment with

ED

rmFGF9 for 24 hrs significantly increased proliferation in both male and female BMSCs in a dose
dependent manner (Fig. 6A). Strikingly, BMSCs from male mice were more responsive to FGF9

PT

than were BMSCs from female mice. At a dose of 5 ng/ml rmFGF9, there was a 209% (p<0.01)

CE

increase in BrdU labeled male cells and a 76% (p<0.05) increase in BrdU labeled female cells,
when compared to sex matched, vehicle treated control cells (Fig. 6A).

AC

We have examined the expression levels of FGFR3 in both bone marrow progenitors (PCs)
and mature osteoblasts (OBs) because FGF9 has the highest affinity for FGFR3 (6,13,14). It was
found that the expression level of FGFR3 mRNA was much higher in mature OBs regardless of
gender and genotype (supplemental Fig. 2A). We also assessed whether exogenous FGF9 would
produce anabolic effects in maturing OBs due to their high level of expression of FGFR3. In this
study, the BMSCs from male and female wild type mice were cultured separately. FGF9 at a dose
of 5ng/ml was administered to OBs from day 14 to day 21 post culture, mRNA levels of the

13
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osteogenic marker genes including osterix, Runx2, alkaline phosphatase, type 1 collagen and
osteocalcin were measured using real time PCR. It was found that mRNA levels of these bone
marker genes were decreased by FGF9 treatment regardless of gender (Supplemental Fig. 2B and
2C).

T

FGF9 Stimulates Proliferation of BMSCs through Akt1 Signaling Pathway

IP

Inhibition of Akt activity by adding the Akt inhibitor MK-2206 (1µM) completely

CR

eliminated the stimulatory effect of FGF9 on osteoblast precursor proliferation in vitro (Fig. 6B).
Additionally, levels of Akt1and phosphorylated Akt1 in the confluent BMSCs treated with FGF9

US

were measured by western blot. It was found that exogenous FGF9 stimulated BMSC proliferation

AN

by mainly increasing phosphorylation of Akt1 (Fig. 6C), a result in line with the previous finding
that loss of Akt1 was shown to be deleterious to osteoblast precursor development, leading to lower

AC

CE

PT

ED

M

bone mass in male (but not female) mice (30).

14
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Discussion
FGF9 is critical for skeletal development (6-9). It has been reported that FGF9 is expressed
in the proximity of the developing skeleton and that FGF9 null mice exhibited a limb phenotype
with rhizomelia (12). FGF9 is expressed at low levels in osteoprogenitor cells, but is highly

T

expressed in mature osteoblasts (31). The physiological role of osteoblast-derived FGF9 in skeletal

IP

homeostasis is unknown. Our results show that deletion of Fgf9 in osteoblasts led to a significant

CR

decrease in both cancellous and cortical bone in young adult male mice. Surprisingly, the specific
deletion of FGF9 had no such effect in female mice. We have previously observed that Fgf9

US

expression in osteoblasts is regulated by G protein signaling (4). Activation of Gs signaling or

AN

increasing intracellular level of cAMP, both conditions producing strong bone formation (2,3),
down-regulated the expression of Fgf9 in mature osteoblasts. This led us to hypothesize that

M

osteoblast-derived FGF9 might play a negative role in skeletal anabolism. However, deletion of

ED

Fgf9 in osteoblasts resulted in an osteopenic phenotype, as evidenced by a decreased trabecular
bone fractional volume with decreased bone formation at trabecular bone surfaces in male Fgf9OB-/-

PT

mice. Histomorphometry also demonstrated that FGF9 deficiency resulted in a decrease in number

CE

of OBs and mineralized surface (MS/BS) but had no effect on MAR at the distal femur, suggesting
that deletion of FGF9 in osteoblasts might not affect the speed of mineralization, but the number of

AC

osteoblasts, at the trabecular surface. In the diaphysis of long bones (where mature osteoblasts and
osteocytes are the dominant osteoblast lineage cell types) loss of Fgf9 led to increased expression of
markers of mature osteoblasts, including Ocn, Dmp1, and Col1. However, the male Fgf9OB-/- mice
exhibited a decreased cortical bone thickness with a decreased cortical bone formation rate.
Collectively, these findings suggest that mature osteoblasts serve as an important source of FGF9
and that secreted FGF9 regulates bone formation in adult male mice in a cell non-autonomous
manner.
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FGFs including FGF9 comprise the most common subfamily that transduces signals through
FGFR tyrosine kinases. These polypeptides can be retained in the extracellular matrix in the vicinity
of their secreting cells and act as autocrine and/paracrine factors (32,33). In previous studies,
exogenous FGF9 has been demonstrated to be pro-osteogenic and to facilitate bone regeneration

T

(17,18). Recently, FGF9 has been found to induce osteoblast proliferation and new bone formation

IP

in a bone organ assay (34). In the present study, we demonstrated that exogenous FGF9 stimulates

CR

bone marrow stromal cell proliferation in a dose dependent manner, a finding similar to that of Lu
et al. (35). These findings support the hypothesis that osteoblast secreted FGF9 serves as a paracrine

US

role to stimulate osteogenesis of bone marrow skeletal stem cells to maintain bone homeostasis.

AN

Akt1 deficiency is reported to decrease bone mass and formation (30,36). FGF9 has been
demonstrated to activate Akt pathways to stimulate steroidogenesis in mouse Leydig cells (37).

M

Akt1 is the major isoform in bone cells and acts to suppress osteoblast apoptosis (36). In the present

ED

study, we demonstrated that FGF9 stimulates the proliferation of BMSCs by activating Akt1.
It is not clear why loss of Fgf9 in osteoblasts resulted in significant bone loss in male mice

PT

while not affecting the female skeleton. Available evidence suggests that there is a collaborative

CE

interaction between FGF9 and the actions of androgens on bone (30,38,39). Firstly, FGF9 has
functions related to sex domination in addition to bone formation. Mice globally lacking Fgf9

AC

display male-to-female sex reversal (40). Secondly, androgens promote proliferation of osteoblast
progenitors and differentiation, in part, through PI3-kinase-Akt signaling pathway (30,41). Of
interest in this regard, global haploinsufficiency of Akt1 in mice also induced a decrease in femoral
bone mass that was seen in males but not females (30). Thirdly, we have demonstrated that FGF9
stimulates the proliferation of BMSCs by activating Akt1. Finally, androgens have potent effects on
osteoblast formation. While androgens maintain trabecular bone mass and integrity, they favor
periosteal bone formation in men (42). These findings are consistent with the bone phenotype of
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FGF9 conditional knockout mice, in which deletion of Fgf9 reduced cortical bone by decreasing
both periosteal and cancellous bone formation. Collectively, the growth factor, FGF9 may serve as a
mediator of bone anabolic signaling of androgen/Akt1 in osteoblasts.
The effects of FGF9 on osteoblasts and progenitors are complex. In addition to delivering a

T

mitogenic signal in a variety of cells, FGF9 is also involved in cell differentiation, motility, and

IP

survival (43). Experiments have suggested that FGF9 serves as an endogenous inhibitor of

CR

chondrocyte differentiation (6,44). However, the role of FGF9 on the differentiation of OBs is not
clear. FGF9 is known to signal mainly through FGFR3 in bone (13). In this study, we found that the

US

expression levels of FGFR3 were higher in mature OBs than bone marrow progenitor cells,

AN

independent of gender and genomic difference (Supplemental Figure 2A) and that addition of
FGF9 inhibited the expression of osteogenic marker genes in both male and female mature OBs

M

(Supplemental Figure 2B and 2C). Our results demonstrate that exposure of mature OBs to FGF9

ED

does not elicit an “anabolic” response and that the observed difference in the effects of FGF9 on
bone progenitor cells and mature osteoblasts is not likely related to the levels of FGFR 3. A recent

PT

study has demonstrated that an activating mutation of FGFR3 in osteoblasts does not produce any

CE

obvious bone phenotype (45), supporting our conclusion. The seemingly inconsistent results
between the Fgf9 OB-/- mice and these in vitro cell experiments may be due to functional redundancy

AC

between FGF ligands (5,11). Fgf9 belongs to the canonical Fgf subfamily, Fgf9/16/20 (5).
Canonical Fgfs mediate biological response by binding to and activating FGFRs. Although each
canonical FGF has distinct receptor binding specificity, each member of an FGF subfamily has
similar receptor specificity (19). The specific role of these receptors in mediating responses to FGF9
in bone remains to be elucidated. Given its role in fracture regeneration (17) and in diseases such as
oncogenesis (46) and tumor metastasis (34,47,48), FGF9 and its signaling pathways are attractive
targets for therapy.
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In conclusion, our results suggest that mature osteoblasts are a possibly important source of
FGF9, positively regulating skeletal homeostasis in male mice. Osteoblast-derived FGF9 may serve
a paracrine role to maintain the osteogenic progenitor cell population through activation of Akt1
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signaling.
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Figure Legends
Figure 1. Establishment of a transgenic mouse model with the conditional deletion of Fgf9 in
osteoblasts. A) Schematic showing the transgenic mouse model used in this study. B). The Cre

T

recombinase is demonstrated to be expressed in osteoblasts (OBs) and osteocytes (OCTs) in adult

IP

Coll (2.3)-Cre; td/Tomato Red mice. C) Reverse transcription end point PCR demonstrated a

fl/fl

CR

successful excision of Fgf9 fragment in the RNA extract from the long bones of the Coll (2.3); Fgf9
(Fgf9 OB-/-) mice. D) Real time PCR assessment of the level of Fgf9 mRNA (relative to GAPDH)

AN

US

in the long bones of 3 months old Fgf9 OB-/- mice. *p<0.05 vs. littermate controls (Fgf9 fl/fl).

Figure 2. Assessment of cancellous bone mass at distal femur in the 3 month old male and female
OB-/-

mice. A). Representative CT 3D reconstruction images of the distal femurs. B and C).

M

Fgf9

ED

Histomorphometry of cancellous bone at the distal femurs. BV, bone volume; TV, tissue volume;
Tb.Th, trabecular thickness, Tb.Sp, trabecular separation; MS, mineralizing surface; MAR, mineral

PT

apposition rate, BFR, bone formation rate. ** p< 0.01, *p<0.05 vs. the sex-matched littermate

CE

controls. ### p<0.001, ## p<0.01 vs. age-match Fgf9 fl/fl mice with the same genotype.

AC

Figure 3. Assessment of cortical bone at tibio-fibular junction (TFJ) in the 3 month old male and
female Fgf9 OB-/- mice. A). Representative 3D reconstruction images of CT scan at the TFJ. B and
C). Histomorphometry of cortical bone at the TFJ. Ps.Pm, periosteal perimeter; Ec.Pm, endosteal
perimeter; Ct.Th, cortical thickness; Med.Ar, bone marrow area; Ps.BFR, periosteal bone formation
rate, Ec.BFR, endosteal bone formation rate. ** p< 0.01, *p<0.05 vs. the sex-matched littermate
controls.
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Figure 4. Determination of mRNA levels of osteogenic marker genes in the long bones of the 3
month old Fgf9 OB-/- mice. *p<0.05 vs. the sex-matched littermate controls.

Figure 5. Assessment of bone resorption in the 3 months old Fgf9

OB-/-

mice. N. OC, number of

IP

T

osteoclasts; BS, the length of bone surface. PYD, pyridinoline.

CR

Figure 6. Effects of exogenous FGF9 on proliferation of the cultured bone marrow stromal cells
(BMSCs). The BMSCs from wild type mouse were treated with exogenous FGF (5ng/ml) for 24

US

hrs. A and B) Assessment of BMSC proliferation in the absence or presence of Akt inhibitor, MK-

AN

2206 (1M). Cell proliferation was determined by BrdU incorporation assay. C) Determination of

AC

CE

PT

ED

M

Akt1 activation in BMSCs by FGF9 (5ng/ml) using Western blots.
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Table 1. CT assessment of distal femur and tibiofibular junction in 3 month of Fgf9 OB-/- and
littermate Fgf9 fl/fl mice.
Parameters
Male
Female
Fgf9 fl/fl
Fgf9 OB-/Fgf9 fl/fl
Fgf9 OB-/Distal Femur
BV/TV (%)
12.54  2.09
9.252  1.59 ***
13.29  2.43
12.86  1.40
Tb.N (1/mm)
5.059  0.457
4.773  0.537
4.873  0.347
4.845  0.595
Tb.Th (µm)
40.62  2.63
36.18  2.17 **
42.04  4.35
43.00  4.35
Tb.Sp (µm)
197.1  18.4
212.5  26.86
205.7  17.46
208.8  28.61
Tibio-fibular
Junction
TV (mm3)
0.3056  0.025
0.2890  0.016
0.2883  0.018 0.2798  0.039
BV (mm3)
0.2116  0.017 0.1965  0.014* 0.2101  0.018 0.2030  0.021
Ct. Th (mm)
0.2251  0.014 0.2118  0.017* 0.2356  0.019 0.2316  0.011
Data are presented as Mean  SD. BV, bone volume; TV, tissue volume; Tb.N, trabecular Number;
Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; Ct.Th, cortical thickness. *** p<0.001, **
p<0.01, * p<0.05 vs. littermate control mice. Statistic analysis was determined by two-way
ANOVA.
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